3 November 2025

Mandatory notification of trade

Oslo, 3 November 2025: Reference is made to the stock exchange announcement published by Oncoinvent ASA (the “Company”) on 29 October 2025 regarding the completion of the merger between the Company and the former Oncoinvent ASA (reg. no. 995 764 458) (“Oncoinvent”) (the “Merger”).

2025-11-03 vederlags aksjer

PDMR - Attachment allocation of consideration shares

In connection with completion of the Merger, the former shareholders of Oncoinvent, including certain primary insiders of the Company and their close associates, have today been allocated consideration shares in the Company. More information about the allocation of consideration shares is included in the Prospectus published on 28 October 2025. 

Please see the attached forms for further details on the allocation of consideration shares in the Merger to the Company’s primary insiders and their close associates.

For more information, please contact:

Øystein Soug, Chief Executive Officer
Email: soug@oncoinvent.com

About Oncoinvent ASA
Oncoinvent is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. The lead product candidate, Radspherin®, uses the alpha-emitting radionuclide radium-224, directly targeting micro-metastases post-surgery, harnessing the benefits of modern radiopharmaceuticals without the complexities of biological targeting. Oncoinvent is investigating the safety and efficacy of Radspherin® in a clinical development program in two indications. One Phase 1 trial and one Phase 1/2a trial have been completed and one randomized Phase 2 trial is currently ongoing in the US, UK and Europe. Early clinical efficacy data are highly encouraging, and no serious toxicity or safety concerns have been reported to date. The Oncoinvent team consists of approx. 40 employees and runs a state-of-the-art manufacturing facility to produce drug products for clinical trials in Nydalen, Oslo. Oncoinvent is listed on Euronext Oslo Børs.

This information is subject to the disclosure requirements in article 19 of Regulation EU 596/2014 (the EU Market Abuse Regulation) and Section 5-12 of the Norwegian Securities Trading Act. 

Øystein Soug

Chief Executive Officer

soug@oncoinvent.com

Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.  

Mr. Soug holds an MSc in Economics and Financial Markets from Universität St. Gallen in Switzerland in 1997

close

Anders Månsson

Chief Executive Officer

mansson@oncoinvent.com

Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.

Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.

close